Concurrent use of oral erythromycin and strong inhibitors of CYP3A should be avoided, according to research published in The New England Journal of Medicine.
Concurrent use of oral erythromycin and strong inhibitors of CYP3A should be avoided, according to research published in TheNew England Journal of Medicine.
Researchers found that the rate of sudden death from cardiac causes was 5 times as high (incidence-rate ratio, 5.35; 95% CI, 1.72–16.64; P=.004) among patients who concurrently used erythromycin and CYP3A inhibitors (nitroimidazole antifungal agents, diltiazem, verapamil, troleandomycin), compared to those who had not used CYP3A inhibitors or the study antibiotic medications. The rate of sudden death from cardiac causes was twice as high (incidence-rate ratio, 2.01; 95% CI, 1.08–3.75; P=.03) among patients currently using erythromycin (n=5,305 person-years) as those who had not used any of the study antibiotic medications. There was no significant increase in the risk of sudden death among former users of erythromycin (n=111,779 person-years) (incidence-rate ratio, 0.89; 95% CI, 0.72–1.09; P=.26) or among those who were currently using amoxicillin (n=6,846 person-years) (incidence-rate ratio, 1.18; 95% CI, 0.59–2.36; P=.65).
The population-based study included 1,476 cases of sudden death from cardiac causes and 1,249,943 person-years of follow-up among a Tennessee Medicaid cohort between January 1, 1988, and December 31, 1993. Participants were aged 15 to 84 years (mean age 45; 70% female), not residing in a long-term care facility, and had no life-threatening noncardiac illness. Sudden death was defined as a sudden fatal condition caused by ventricular tachyarrhythmia in the absence of a known noncardiac condition.
SOURCE Ray WA, Murray KT, Meredith S, Narashimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More